Explore the Agenda
7:30 am One-to-One Partnering Meetings Scheduled
The earlybird catches the worm. Set day two up for success with scheduled 1-2-1 meetings ahead of day two content, or grab a coffee and arrive early to catch key contacts before the day starts.
8:40 am Day Two Agenda Starts
How Should Emerging Companies Prioritize Non-Oncology Indications?
8:45 am Expansion Potential: Advancing Degradation into New Indications & Beyond “Classic” Degraders
- Highlighting innovations in non-E3 ligase mechanisms, and discussing which modality fits which disease class?
- Overcoming target identification bottlenecks for immunology and CNS targets. Should companies prioritize diseases with validated pathways but poor druggability, or tissues where degrader PK/ PD is already known?
- As pharma lean towards platforms with broad disease reach, what non-oncology data “moves the needle”?
9:15 am One-to-One Partnering Meetings Scheduled.
With presentation and introductions prioritized in the Day One schedule, Day Two hosts extended meeting breaks, so you can sit down with key contacts, prepared with insights on their expectations, before the conference ends.
Novel Payloads & Combinations as the New Value Driver in ADCs
8:45 am Reflecting on the First Attempts with Novel Payloads, & What we are Doing Differently Now
- What is the path to success for novel payloads, including how to navigate early assessment of payload platforms?
- What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success?
- Discussing the panellists’ approach to business development. What would a win/ win business deal look like that focuses on payloads?
9:15 am One-to-One Partnering Meetings Scheduled.
With presentation and introductions prioritized in the Day One schedule, Day Two hosts extended meeting breaks, so you can sit down with key contacts, prepared with insights on their expectations, before the conference ends.
Is Being “Different” Now Mandatory? Modality Differentiation in a Hyper Competitive Market
8:45 am What can be Improved Upon for Existing Drugs?
- Discussing approaches to differentiate assets targeting competitive targets
- With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
- Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes
9:15 am One-to-One Partnering Meetings Scheduled.
With presentation and introductions prioritized in the Day One schedule, Day Two hosts extended meeting breaks, so you can sit down with key contacts, prepared with insights on their expectations, before the conference ends.
11:30 am Investor Networking Session
Navigating Investor Expectations in a Market Favouring Later Clinical Investments
11:30 am Investor Icebreaker Panel Discussion: When Being Selective, where will Investors Invest? What’s Driving Capital in 2026/27?
- How are each of the modality landscapes discussed facilitating successful VC exits and what does that mean for the future of investment in these areas?
- How have changes to the barrier to entry for new innovations fed through into investment?
- What will drive or inhibit future investment in these target modalities?
- How to progress discussions with investors. What is expected and helpful to understand from biotech, from the investor perspective?
12:00 pm Investor Introduction Tables: Sit, Connect & Break the Ice
Starting with a short investor panel introducing investor interests and moving into an organised networking session.
Mirroring the Pharma Introduction Tables, select the investors that best align with your organisation’s stage and objectives, and join their networking table for 30-minutes. Share business cards or ask a followup question from the panel with your target investor to tick off another key connection at the conference.
Experiences & Economics of Successful Partnerships: Faster De-Risking to Drive Better Science
11:30 am Discussing the Asia Trend & Partnering with Asia Biotech to Accelerate Own Development
- How has China changing the accepted barrier to innovation shaped decision making in the West?
- Opportunities and challenges in partnering with regions across Asia
- Sharing opinions on repeatable data packages from Asia as reference of data package expectations in discovery work, including thoughts on how data to date is playing through as real trends
12:00 pm From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence
- Integrating pan-cancer or broadly applicable targets while maintaining specificity, and using this to evidence a scalable, differentiated discovery engine without compromising safety
- How do we determine which targets align with a given modality’s safety, selectivity and therapeutic potential?
- Sharing experience demonstrating the validation of a credible platform, including evolution from platform narrative to an asset-led story
- Discussing types of deals possible for platforms versus assets, and what is the minimum evidence needed for a deal?
12:30 pm Lunch Break & Networking Opportunity
12:30 pm One-to-One Partnering Meetings Scheduled
Grab some lunch ahead of more meetings across the middle of day one. Sit down more casually with other delegates for ad hoc connections or join those you’ve prearranged to meet.
From Seed to Strategy: Positioning Differentiation for Smart BD Engagement
2:00 pm How Seed Stage Biotech Navigate BD Engagement
- Discussing unique constraints of seed-stage companies when approaching BD engagement
- Maintaining relationships with big pharma and VCs when data is early and limited
- Outlining opportunities for creative deal structures, and when and where they would be appropriate
“Why Now” for Platforms: Pairing Targets with Modalities to Maximize Clinical Viability
2:30 pm Which Platform Technologies are Widening the Immunology & Oncology Fields?
- How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
- How are we are validating new, and assessing novel versus de-risked targets?
- What type of clinical data would lead the field to reassess assumptions on a target?
3:00 pm Finding a Gap: Achieving Good Response Rates in Difficult Tumor Types
- How do established payloads compare in their ability to drive meaningful clinical responses?
- Have historically pursued targets lacked sufficient expression or accessibility to enable effective tumor penetration?
- What role can mechanisms play in increasing efficacy?